Denali Therapeutics (DNLI) Other Operating Expenses (2024)

Denali Therapeutics (DNLI) reported Other Operating Expenses of $14.5 million for Q1 2024.

Denali Therapeutics (DNLI) has 1 years of Other Operating Expenses data on file, last reported at $14.5 million in Q1 2024.

  • Quarterly Other Operating Expenses changed N/A year-over-year to $14.5 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $14.5 million (changed N/A YoY) and the FY2024 annual result came in at $14.5 million, changed N/A from the prior year.
  • Other Operating Expenses steadied at $14.5 million in Q1 2024 per DNLI's latest filing.
  • Across five years, Other Operating Expenses topped out at $14.5 million in Q1 2024 and bottomed at $14.5 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Denali Therapeutics 3.82 Bn 3.82 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 14.54 Mn